Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-α

Molecular Pharmacology

Volumn 72, Issue 4, 2007, Pages 934-946

  Dasgupta, Subhajit ^a   Roy, Avik ^a   Jana, Malabendu ^a   Hartley, Dean M ^a   Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GEMFIBROZIL; INTERLEUKIN 4; MYELIN; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR GATA 3;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; DRUG DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HYPERLIPIDEMIA; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SWISS JAMES LAMBERT MOUSE; T LYMPHOCYTE;

ANIMALS; ANTILIPEMIC AGENTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GATA3 TRANSCRIPTION FACTOR; GEMFIBROZIL; INTERFERON TYPE II; INTERLEUKIN-4; MALE; MICE; MICE, KNOCKOUT; PPAR ALPHA; TH1 CELLS; TH2 CELLS;

EID: 34748917549     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.033787     Document Type: Article

References (38)

1. Akama KT, Albanese C, Pestell RG, and Van Eldik LJ (1998) Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NF-κB-dependent mechanism. Proc Natl Acad Sci U S A 95:5795-5800.
2. Benveniste EN (1997) Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75:165-173.
3. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, and Robins SJ (2001) Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103:2828-2833.
4. Bö L, Dawson TM, Wesselingh S, Mork S, Choi S, Kong PA, Hanley D, and Trapp BD (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36:778-786.
5. Brosnan CF, Battistini L, Raine CS, Dickson DW, Casadevall A, and Lee SC (1994) Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci 16:152-161.
6. Connelly JF (1994) Interferon beta for multiple sclerosis. Ann Pharmacother 28:610-616.
7. Cunard R, Ricote M, Campli DD, Archer DC, Kahn DA, Glass CK, and Kelly CJ (2002) Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 168:2795-2802.
8. Dasgupta S, Zhou Y, Jana M, Banik NL, and Pahan K (2003) Sodium Phenyl acetate inhibits adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice at multiple steps. J Immunol 170:3874-3882.
9. Dasgupta S, Jana M, Zhou Y, Fung YK, Ghosh S, and Pahan K (2004) Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 173:1344-1354.
10. Ding MZ, Zhang M, Wong JL, Rogers NE, Ignarro LJ, and Voskuhl RR (1998) Cutting edge-Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 160:2560-2564.
11. Drapier JC and Hibbs JB (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine- dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 140:2829-2838.
12. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, and Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879-887.
13. Du C, Khalil MW, and Sriram S (2001) Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol 167:7094-7101.
14. Hsu HC, Lee YT, Yeh HT, and Chen MF (2001) Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia. J Lab Clin Med 137:414-421.
15. Jones DC, Ding X, and Daynes RA (2002) Nuclear receptor PPAR-α is expressed in resting murine lymphocytes: the PPAR-α in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 277:6838-6845.
16. Jones DC, Ding X, Zhang TY, and Daynes RA (2003) Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. J Immunol 171:196-203.
17. Kadenatsi IB, Levchuk SN, Agapitova IV, Glezer MG, Domvrovskii VS, Mukumov MR, and Firsov AA (1995) Determination of gemfibrozil by HPLC in pharmacokinetic studies. Pharma Chem J 29:732-735.
18. Kim CK, Jae JP, Hwang HR, Ban E, Maeng JE, Kim MK, and Piao XL (2006) Simple and sensitive HPLC method for determination of gemfibrozil in human plasma with fluorescence detection. J Liq Chromatogr Relat Technol 29:403-414.
19. Lemberger T, Desvergne B, and Wahli W (1996) Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12:335-363.
20. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PA, and Racke MK (2004) Peroxysome proliferator- activated receptor a agonists as therapy for autoimmune disease. J Immunol 172:5790-5798.
21. Martin R, McFarland HF, and McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10:153-187.
22. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, and Lane TE (1993) Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J Immunol 151: 2132-2141.
23. Miller A (1997) Current and investigational therapies used to alter the course of disease in multiple sclerosis. South Med J 90:367-375.
24. Mitrovic B, Ignarro LJ, Montestruque S, Smoll A, and Merrill JE (1994) Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience 61:575-585.
25. Nathan C (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J 6:3051-3064.
26. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Bloomfield HE, and Robins SJ (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113:1556-1563.
27. Ouyang W, Lohning M, Gao Z, Assenmacher M, Ranganath S, Radbruch A, and Murphy KM (2000) STAT6-independent GATA3 autoactivation directs IL-4 independent TH2 development and commitment. Immunity 12:27-37.
28. Pahan K and Schmid M (2000) Activation of NF-κB in spinal cord of experimental allergic encephalomyelitis. Neurosci Lett 287:17-20.
29. Pahan K, Jana M, Liu X, Taylor BS, Wood C, and Fischer SM (2002) Gemfibrozil, a lipid lowering drug, inhibits the induction of nitric oxide synthase in human astrocytes. J Biol Chem 277:45984-45991.
30. Parkinson JF, Mitrovic B, and Merrill JE (1997) The role of nitric oxide in multiple sclerosis. J Mol Med 75:174-186.
31. Radi R, Beckman JS, Bush KM, and Freeman BA (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem 266:4244-4250.
32. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, et al.; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VAHIT: a randomized controlled trial. JAMA 285:1585-1591.
33. Saha RN and Pahan K (2006) Up-regulation of BDNF in astrocytes by TNF-α: a case for the neuroprotective role of this cytokine. J Neuroimmun Pharmacol 1:212-222.
34. Samdani AF, Dawson TM, and Dawson VL (1997) Nitric oxide synthase in models of focal ischemia. Stroke 28:1283-1288.
35. Superko HR, Berneis KK, Williams PT, Rizzo M, and Wood PD (2005) Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. Am J Cardiol 96: 1266-1272.
36. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, and Glimcher LH (2000) A novel transcription factor, T bet, directs TH1 lineage commitment. Cell 100:655-669.
37. Tuohy VK, Sobel RA, and Less MB (1988) Myelin proteolipid protein-induced experimental allergic encephalomyelitis. J Immunol 140:1868-1873.
38. Xu J, Storer PD, Chavis JA, Racke MK, and Drew PD (2005) Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 81:403-411.